Weekly Recap | CVS Health -0.35%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.CVS Health (CVS) fell 0.35% this week to $86.16, underperforming the S&P 500 by about 1.5 percentage points. Trading was choppy: the stock opened Monday at $86.69, pushed as high as $89.93 midweek, then pulled back into Friday’s close at $86.16 after touching $85.80 in the session low. Weekly amplitude was 5.08%, and daily volume ran about 40% above the stock’s own median.
The Week
CVS Health (CVS) fell 0.35% this week to $86.16, underperforming the S&P 500 by about 1.5 percentage points. Trading was choppy: the stock opened Monday at $86.69, pushed as high as $89.93 midweek, then pulled back into Friday’s close at $86.16 after touching $85.80 in the session low. Weekly amplitude was 5.08%, and daily volume ran about 40% above the stock’s own median.
Key Events
Medicare star ratings dominated the narrative. On Monday, Aetna and UnitedHealthcare were reported tightening their 2027 Medicare Advantage networks, and CVS confirmed an 11 November pre-market call for third-quarter results. Friday was the key session: after CMS released 2027 ratings, CVS said more than 69% of its Medicare Advantage members sit in plans rated 4 stars or higher, with Aetna calling the outcome a boost to confidence in returning to appropriate margins. TD Cowen, however, warned the same day that star-rating setbacks could pressure earnings, and CVS was down as much as 3.17% in pre-market trading. Elsewhere, the first pharmacy-focused store opened in the Boston area, MMR vaccine availability was flagged amid a measles outbreak, and a law firm announced an investigation into officers and directors.
Analyst Ratings
Of 27 covering firms, 18 rate it buy and 7 rate it overweight, with 2 neutral and none at underweight or sell. The consensus rating is strong buy, with a consensus target of $115.76, roughly 34% above the current price. The target range of $103 to $145 points to wide disagreement. CVS ranks second among 53 companies in its healthcare services industry for analyst ratings.
The Week Ahead
US CPI and core CPI land on Thursday, with markets watching the inflation path. Further out, CVS reports third-quarter results before the market opens on 4 November, with estimates at $1.29 earnings per share and $104.8bn revenue. Aetna’s margins and Medicare Advantage membership mix will be the clearest read on whether the ratings outcome translates into earnings.
In Short
Broker sentiment leans strongly positive, with the consensus target about 34% above spot, while the stock trades below its 20-day average and large-lot flows turned net seller in the latest session. The star-rating update cuts both ways: it supports Aetna’s margin story but leaves the near-term earnings question open. The next signposts are the US inflation prints and the third-quarter report.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.